September 8, 2020

FDA Approves IDE for CARENET-III Pivotal Trial of InspireMD’s CGuard Carotid Stent System

September 8, 2020—InspireMD, Inc., the Israel-based developer of the CGuard embolic prevention system for the prevention of stroke caused by carotid artery disease, announced FDA approval for the company to proceed with the CARENET-III pivotal study of the CGuard carotid stent system for prevention of stroke in patients in the United States.

The company advised that the CARENET-III study would be composed of 315 patients enrolled at up to 40 institutions in the United States. The company will provide additional details as plans advance.

Subscribe to our weekly newsletter.

Stay informed on the week's top stories including literature summaries, device approvals, guideline changes, and more. Plus, get our latest issues & supplements delivered to your inbox each month.

September 8, 2020

FDA Approves IDE for CARENET-III Pivotal Trial of InspireMD’s CGuard Carotid Stent System

Current Issue

Keep In Touch